聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 48 分钟 21 秒 前

Clarus Therapeutics Appoints Patrick Shea Chief Commercial Officer

周三, 05/21/2014 - 14:53
Company Adds Pharmaceutical Veteran With Nearly 30 Year Sales and Marketing Track Record NORTHBROOK, Ill., May 21, 2014 -- (Healthcare Sales & Marketing Network) -- Clarus Therapeutics, Inc., a men's health specialty pharmaceutical company focused on th...
Biopharmaceuticals, Personnel
Clarus Therapeutics, REXTORO, testosterone

Boston Scientific Reports Strong Performance Data For SYNERGY(TM) Stent System

周三, 05/21/2014 - 14:50
EVOLVE Study Data Presented Today at EuroPCR 2014 Also Demonstrate Excellent Safety Profile NATICK, Mass., May 21, 2014 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (BSX) reported positive three-year follow-up data for the...
Devices, Interventional Cardiology
Boston Scientific, SYNERGY Stent, drug eluting stent, coronary stent

Proa(R) Medical Receives 510(k) Clearance from FDA for Brella-Spec(TM) Vaginal Speculum for Gynecological and Obstetrical Procedures

周二, 05/20/2014 - 15:09
LOS ANGELES--(Healthcare Sales & Marketing Network)--Proa® Medical, Inc., developer of innovative and practical medical devices for women’s health, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market ...
Devices, FDA
Proa Medical, Brella-Spec, Vaginal Speculum

InspireMD to Showcase Embolic Systems with MicroNet(TM) Technology and Results from MASTER I Trial at EuroPCR Conference

周二, 05/20/2014 - 15:07
Company to Present at European Symposium Titled MGuard™ Embolic Protection Stent: The Importance of Thrombus Management in STEMI Primary PCI BOSTON, May 20, 2014 -- (Healthcare Sales & Marketing Network) -- InspireMD, Inc. ("InspireMD" or the...
Devices, Interventional Cardiology
InspireMD, embolic protection, MicroNet

Spero Therapeutics Appoints Thomas Parr, Ph.D. as Chief Scientific Officer

周二, 05/20/2014 - 15:04
Company assembles Scientific Advisory Board comprised of world-leaders in microbiology and the clinical development of anti-infectives to combat severe infections resulting from highly drug-resistant, gram-negative bacteria CAMBRIDGE, Mass.--(Healthcare...
Biopharmaceuticals, Personnel
Spero Therapeutics

Pharmacyclics appoints Gregory R. Wade to lead Business Development

周二, 05/20/2014 - 14:59
SUNNYVALE, Calif., May 20, 2014 -- (Healthcare Sales & Marketing Network) -- Pharmacyclics, Inc. (the "Company") (PCYC) is pleased to announce that Gregory R. Wade has joined the company as Executive Vice President of Business Development. In hi...
Biopharmaceuticals, Personnel
Pharmacyclics

STENTYS Sirolimus-Eluting Stent Demonstrates Best in Class Efficacy for Heart Attack Patients

周二, 05/20/2014 - 14:57
Final Results from APPOSITION IV Study Presented at EuroPCR: No late loss and perfect strut coverage at 9-months Faster arterial healing compared to conventional drug-eluting stents PRINCETON, N.J. & PARIS--(Healthcare Sales & Marketing Network)--...
Devices, Interventional Cardiology
STENTYS, Self-Apposing Stent, coronary stent, drug eluting stent

Edwards Lifesciences, Medtronic Agree to Global Transcatheter Valve Litigation Settlement

周二, 05/20/2014 - 14:51
All Patent Litigation Between the Companies to Be Dismissed IRVINE, CA--(Healthcare Sales & Marketing Network) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced th...
Devices, Interventional Cardiology, Litigation
Edwards Lifesciences, Medtronic, transcatheter, heart valve

Statement from Pfizer Inc.

周二, 05/20/2014 - 14:45
FINAL PROPOSAL TO ASTRAZENECA NEW YORK--(Healthcare Sales & Marketing Network)--This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the “Code”). It does not represent a firm intention to make an ...
Biopharmaceuticals, Mergers & Acquisitions
Pfizer, AstraZeneca

Pamela Youde Nethersole Eastern Hospital First in Asia to Treat Cancer using TrueBeam 2.0 System for Image-Guided Radiotherapy and Radiosurgery

周一, 05/19/2014 - 12:21
New technology now being used to treat nasopharyngeal and other cancers; stereotactic radiosurgery program for select cancers coming in June HONG KONG, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Pamela Youde Nethersole Eastern Hospital (...
Devices, Oncology
Varian Medical Systems, radiosurgery, radiotherapy, TrueBeam

Nektar Appoints Ivan Gergel, M.D. as Senior Vice President, Drug Development and Chief Medical Officer

周一, 05/19/2014 - 12:16
SAN FRANCISCO, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Nektar Therapeutics (NKTR), a biopharmaceutical company developing novel pain and cancer therapeutics, announced that Ivan Gergel, M.D., will serve as the Company's new Senior Vice P...
Biopharmaceuticals, Personnel
Nektar Therapeutics, naloxegol

Coherus BioSciences Secures $55 million Series C Financing

周一, 05/19/2014 - 12:12
REDWOOD CITY, Calif., May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Coherus BioSciences, Inc. ("Coherus"), a leading biologics platform company focused on biosimilars, announced today the closing of a Series C Preferred investment ro...
Biopharmaceuticals, Venture Capital
Coherus Biosciences, biosimilar

Biocept Announces National Sales Force

周一, 05/19/2014 - 12:06
Oncology Sales Specialists to Deploy Blood-Based Cancer Diagnostics Into Physician Practices and Pharmaceutical Development Markets SAN DIEGO, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Biocept, Inc. (BIOC), a molecular oncology diagnosti...
Diagnostics, Oncology
Biocept, OncoCEE, Circulating Tumor Cells

Ventrus Biosciences to Merge With Assembly Pharmaceuticals

周一, 05/19/2014 - 12:00
New Company, Assembly Biosciences, to Focus on First-in Class Technology for Treatment and Potential Cure of Hepatitis B Virus Infection, Affecting 350 Million Worldwide Projected Multi-Billion Market Opportunity; No Curative Therapy Exists Combined ...
Biopharmaceuticals, Mergers & Acquisitions
Ventrus Biosciences, Assembly Pharmaceuticals, Hepatitis B

Genkyotex Announces New Senior Management and Board Appointments

周一, 05/19/2014 - 11:50
GENEVA & ARCHAMPS, France--(Healthcare Sales & Marketing Network)--Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the appointment of Dr. Jeanette Wood as Chief Scientific Officer and Dr. Joseph McCracken to the Board o...
Biopharmaceuticals, Personnel
Genkyotex, GKT137831, NOX inhibitors

Shire Plans to Submit a New Drug Application to FDA for Lifitegrast for Dry Eye Disease in Adults

周一, 05/19/2014 - 11:45
FDA submission planned for 1st Quarter 2015 Shire forms business unit focused in ophthalmics LEXINGTON, Massachusetts, May 19, 2014 -- (Healthcare Sales & Marketing Network) -- Following a May 15, 2014, meeting with the U.S. Food and Drug Administra...
Biopharmaceuticals, Ophthalmology
Shire plc, dry eye disease, Lifitegrast

OXiGENE Names Experienced Biotech Executive, David J. Chaplin, Ph.D., as President and Chief Executive Officer

周五, 05/16/2014 - 14:26
SOUTH SAN FRANCISCO, Calif., May 16, 2014 -- (Healthcare Sales & Marketing Network) -- OXiGENE, Inc. (OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, announced that David (Dai) Chaplin, Ph.D., has been appoi...
Biopharmaceuticals, Oncology, Personnel
OXiGENE, vascular disrupting agents

Proteon Therapeutics Announces $45 Million of Series D Financing

周五, 05/16/2014 - 14:24
Company Poised to Initiate Phase 3 Trial of PRT-201 for Reduction of AVF Failure in Hemodialysis WALTHAM, Mass.--(Healthcare Sales & Marketing Network)--Proteon Therapeutics Inc., a privately held biopharmaceutical company developing novel, first-in-cla...
Biopharmaceuticals, Venture Capital
Proteon Therapeutics, Elastase, hemodialysis, vascular access

Sorbent Therapeutics Closes First Tranche Of $15 Million Series D Financing

周四, 05/15/2014 - 15:05
Completes Enrollment in Phase 2b Clinical Trial of CLP-1001 for Heart Failure SUNNYVALE, Calif., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- Sorbent Therapeutics, Inc., a biopharmaceutical company developing therapies for cardiovascular a...
Biopharmaceuticals, Cardiology, Venture Capital
Sorbent Therapeutics, Heart Failure

Boston Scientific Announces Definitive Agreement To Acquire Interventional Division Of Bayer AG

周四, 05/15/2014 - 15:01
Acquisition Expected to Strengthen Peripheral Interventions Business and Accelerate Growth in Peripheral Atherectomy and Thrombectomy Categories NATICK, Mass., May 15, 2014 -- (Healthcare Sales & Marketing Network) -- In a move to expand significantly ...
Devices, Interventional, Acquisitions
Boston Scientific, Bayer AG, Bayer Interventional, AngioJet, Thrombectomy

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong